Biogen to Present Key Lecanemab SC Formulation & 3-Year Real-World Data at AAIC 2026
BIIB sits 79% above its 52-week low of $121.05.
Summary
Biogen will present significant updates on its Alzheimer's drug, Lecanemab, at the upcoming AAIC 2026 conference. The presentation will include data on a new subcutaneous (SC) at-home formulation, which could greatly improve patient convenience and access. Additionally, three-year real-world data from the LEADER study will be shared, providing crucial insights into the drug's long-term use, safety, and maintenance dosing. This news follows a period of mixed pipeline updates for Biogen, making positive developments for a key commercialized drug particularly important for its revenue outlook.
At the time of this announcement, BIIB was trading at $217.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32B. The 52-week trading range was $121.05 to $219.72. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.